PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 71):
The antibody of  claim 1 , wherein:\n (a) the antibody is a monoclonal antibody; (b) the antibody is a chimeric antibody, a humanized antibody, a CDR-grafted antibody, or a human antibody; (c) the antibody comprises an Fc region selected from the group consisting of a native Fc region, a variant Fc region, and a functional Fc region; (d) the antibody is a conjugate antibody or is detectably labeled; (e) the antibody is an IgG1 antibody, an IgG2 antibody, or an IgG3 antibody; (f) the antibody is an IgG4 antibody; (g) the heavy chain of the antibody additionally comprises a C-terminal lysine; or (h) the antibody binds to LILRB2 with a dissociation constant (KO of less than 3.0 nM, less than 1.5 nM, less than 1.0 nM, or less than 750 \u03bcM.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7893606319989159
- 35 USC 102 Novelty (BERT): 0.5350630857857929
- Combined Prediction Score: 0.7639308773776037
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 295.31428256506206

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test